BeyondSpring Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
1.65
-0.03
(-1.79%)
Volume:
13,252
52 week range:
0.98 - 3.63
Market Cap:
66.522M
Company Description:
Plinabulin, a selective immune-modulating microtubule-binding agent, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. BeyondSpring Inc. is a clinical stage biopharmaceutical company. Company engages in the development of three small molecule immune agents in preclinical stages; and drug development platform.